Haoxi Health Technology Limited (HAO) Financial Ratios
5 years of historical data (2021–2025) · Communication Services · Advertising Agencies
EV/EBITDA
N/A
—
5yr avg: 121049.80
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.15
↓-100% vs avg
5yr avg: 9289.25
30Y Low23.0·High23.0
ROE
↓
27.1%
↑-96% vs avg
5yr avg: 657.0%
30Y Low20%·High27%
Debt/EBITDA
↓
N/A
—
5yr avg: 1.07
30Y Low0.7·High1.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
HAO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Haoxi Health Technology Limited trades at 0.8x earnings, 100% below its 5-year average of 8123.4x, sitting at the 0th percentile of its historical range. Compared to the Communication Services sector median P/E of 15.3x, the stock trades at a discount of 94%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $5M | $399M | $209.2B | — | — | — |
| Enterprise Value | $-1597388 | $392M | $209.2B | — | — | — |
| P/E Ratio → | 0.85 | 126.06 | 16120.75 | — | — | — |
| P/S Ratio | 0.15 | 12.16 | 4310.75 | — | — | — |
| P/B Ratio | 0.15 | 22.95 | 18555.54 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
HAO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 11.96 | 4310.64 | — | — | — |
| EV / EBITDA | — | — | 121049.80 | — | — | — |
| EV / EBIT | — | 93.54 | 117736.74 | — | — | — |
| EV / FCF | — | — | — | — | — | — |
HAO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Haoxi Health Technology Limited earns an operating margin of -6.1%, below the Communication Services sector average of 1.6%. Operating margins have compressed from 4.2% to -6.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 27.1% indicates solid capital efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 2.8% | 2.8% | 5.7% | 7.3% | 4.0% | 4.7% |
| Operating Margin | -6.1% | -6.1% | 3.5% | 4.2% | 1.7% | 2.6% |
| Net Profit Margin | 11.8% | 11.8% | 2.7% | 3.4% | 1.5% | 2.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | 27.1% | 27.1% | 20.1% | 1923.7% | — | — |
| ROA | 20.9% | 20.9% | 12.9% | 38.7% | 14.6% | 10.8% |
| ROIC | -18.1% | -18.1% | 36.6% | 73.9% | — | — |
| ROCE | -13.6% | -13.6% | 25.4% | 566.7% | — | — |
HAO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $9M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 91.2x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.11 | 0.11 | 0.11 | 0.54 | — | — |
| Debt / EBITDA | — | — | 0.70 | 0.71 | 1.87 | 1.01 |
| Net Debt / Equity | — | -0.38 | -0.48 | -0.23 | — | — |
| Net Debt / EBITDA | — | — | -3.16 | -0.29 | 0.78 | 3.29 |
| Debt / FCF | — | — | — | — | — | 0.41 |
| Interest Coverage | 91.25 | 91.25 | 43.13 | 57.95 | 27.06 | 62.72 |
Net cash position: cash ($9M) exceeds total debt ($2M)
HAO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Haoxi Health Technology Limited's current ratio of 5.05x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.43x to 5.05x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 5.05 | 5.05 | 3.98 | 1.43 | 0.22 | 0.56 |
| Quick Ratio | 5.05 | 5.05 | 2.64 | 0.49 | 0.22 | 0.46 |
| Cash Ratio | 2.22 | 2.22 | 1.72 | 0.47 | 0.15 | 0.01 |
| Asset Turnover | — | 1.52 | 3.13 | 6.32 | 29.76 | 4.57 |
| Inventory Turnover | — | — | 8.85 | 10.88 | — | 25.97 |
| Days Sales Outstanding | — | 58.82 | 26.70 | 0.86 | 0.09 | 56.01 |
HAO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Haoxi Health Technology Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 100.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | 100.0% | 0.8% | 0.0% | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $2M | $12M | $11M | $10M | $10M |
Peer Comparison
Compare HAO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 HAOYou | $5M | 0.8 | — | — | 2.8% | -6.1% | 27.1% | -18.1% | — |
 BTBT | $726M | -7.2 | — | — | 21.4% | -49.8% | -12.1% | -5.8% | — |
 CLPS | $27M | -3.7 | — | — | 20.9% | -4.0% | -11.6% | -7.9% | — |
 AIXI | $2M | -0.0 | — | — | 44.4% | -783.6% | — | — | — |
 RCON | $10M | -0.7 | — | — | 23.0% | -86.5% | -9.0% | -10.6% | — |
 CNET | $3M | -1.4 | — | — | 7.7% | -42.3% | -43.6% | -44.2% | — |
 GXAI | $9M | -2.3 | — | — | 89.4% | -254.3% | -26.6% | -52.2% | — |
 KXIN | $5M | -0.1 | — | — | — | — | -102.3% | -36.0% | — |
 BIDU | $38B | 64.4 | 39.3 | — | 43.9% | -4.5% | 1.9% | -1.2% | 11.6 |
 DOYU | $140M | -34.6 | -18.9 | — | 12.8% | 0.3% | -0.9% | 0.5% | 0.2 |
 IQ | $998M | -33.4 | 1.4 | 695.9 | 21.1% | 6.0% | -0.2% | 0.7% | 1.2 |
| Communication Services Median | — | 15.3 | 9.7 | 11.2 | 48.5% | 1.6% | 2.0% | 2.6% | 3.6 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
HAO — Frequently Asked Questions
Quick answers to the most common questions about buying HAO stock.
What is Haoxi Health Technology Limited's P/E ratio?
Haoxi Health Technology Limited's current P/E ratio is 0.8x. The historical average is 126.1x.
What is Haoxi Health Technology Limited's ROE?
Haoxi Health Technology Limited's return on equity (ROE) is 27.1%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 23.6%.
Is HAO stock overvalued?
Based on historical data, Haoxi Health Technology Limited is trading at a P/E of 0.8x. Compare with industry peers and growth rates for a complete picture.
What are Haoxi Health Technology Limited's profit margins?
Haoxi Health Technology Limited has 2.8% gross margin and -6.1% operating margin.